Thomas D A, Myers M A, Wichert B, Schreier H, Gonzalez-Rothi R J
Department of Medicine, University of Florida College of Medicine, Gainesville.
Chest. 1991 May;99(5):1268-70. doi: 10.1378/chest.99.5.1268.
Administering liposome-encapsulated drugs by aerosol is a feasible way of targeting drugs to the lungs. Prior to clinical application of aerosolized liposomes as drug carriers, their relative safety must be established. We evaluated the effects of inhaling nondrug-containing liposomes (15 and 150 mg of lipid per milliliter) for 1 h on pulmonary function and on oximetry in ten healthy nonsmoking volunteers. Spirometry was performed prior to and at intervals after inhalation, and subjects were monitored with pulse oximetry. Liposome inhalation was well tolerated, and no oxygen desaturation, decrements in pulmonary function, or side effects were noted. We conclude that inhalation of small particle aerosols of SPC liposomes produces no acute deleterious effects on pulmonary function in healthy subjects.
通过气雾剂给药脂质体包裹的药物是将药物靶向肺部的一种可行方法。在将雾化脂质体作为药物载体临床应用之前,必须确定其相对安全性。我们评估了10名健康不吸烟志愿者吸入不含药物的脂质体(每毫升15和150毫克脂质)1小时对肺功能和血氧饱和度的影响。在吸入前和吸入后的不同时间间隔进行肺活量测定,并使用脉搏血氧饱和度仪对受试者进行监测。吸入脂质体的耐受性良好,未观察到氧饱和度下降、肺功能减退或副作用。我们得出结论,吸入小颗粒的大豆磷脂酰胆碱脂质体气雾剂对健康受试者的肺功能没有急性有害影响。